$68.8 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | VENTYX BIOSCIENCES INC | $26,056,000 | +134.0% | 746,370 | -18.0% | 37.85% | +144.9% | |
| ICOSAVAX INC | $11,092,000 | -44.9% | 3,510,228 | 0.0% | 16.11% | -42.3% | ||
| HILLEVAX INC | $9,552,000 | +56.4% | 558,923 | 0.0% | 13.88% | +63.6% | ||
| TALS | TALARIS THERAPEUTICS INC | $7,713,000 | -41.7% | 2,932,606 | 0.0% | 11.20% | -39.0% | |
| KZR | KEZAR LIFE SCIENCES INC | $7,135,000 | +4.1% | 828,711 | 0.0% | 10.36% | +9.0% | |
| JASPER THERAPEUTICS INC | $4,619,000 | -59.1% | 5,852,982 | 0.0% | 6.71% | -57.2% | ||
| ELEV | ELEVATION ONCOLOGY INC | $2,678,000 | -19.3% | 2,370,142 | 0.0% | 3.89% | -15.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.